<DOC>
	<DOCNO>NCT00120328</DOCNO>
	<brief_summary>The purpose study determine whether avosentan ( SPP301 ) effective decrease morbidity mortality patient diabetic nephropathy .</brief_summary>
	<brief_title>To Determine Effects Avosentan Doubling Serum Creatinine , End Stage Renal Disease Death Diabetic Nephropathy</brief_title>
	<detailed_description>Diabetic nephropathy become leading cause end stage renal disease ( ESRD ) western world , account approximately 40 % new case US , 20 30 % Europe . Current treatment diabetic nephropathy usually try deal underlying diabetes aim reduce cardiovascular risk factor hypertension , hyperglycemia , smoke dyslipidemia . A recently approve drug irbesartan losartan ( type 2 diabetic nephropathy ) renoprotective activity beyond antihypertensive effect . However , morbidity mortality rate remain high . Avosentan may positive effect reduce amount protein lose urine case help treat patient diabetic nephropathy .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<criteria>Male female patient 21 80 year age , inclusive Patients type 2 diabetes mellitus diagnose least 3 year receive oral antidiabetic treatment and/or insulin Female patient either : Post menopausal &gt; = 2 year ; Surgically sterile ; Or , sexually active childbearing potential , use double contraception , least one method barrier contraception . Women childbearing potential ( define surgically sterile , hysterectomy 2 year ' postmenopausal ) must negative pregnancy test screen randomisation . Pregnancy test repeat monthly study Proteinuria define ACR &gt; = 35mg/mmol Male patient serum creatinine 1.3 3.0 mg/dL Female patient serum creatinine 1.2 3.0 mg/dL On standard treatment diabetic nephropathy ( ACE inhibitor , ARBs combination thereof ) least 6 month screen . Patients intolerant ACE inhibitor ARBs allow enter study Able provide write informed consent prior study participation Patients type 1 diabetes mellitus Patients proteinuria nondiabetic origin Patients renal transplant Patients undergone nephrectomy Patients estimate GFR &lt; = 15 mL/min Patients blood pressure &gt; = 160/100 mmHg without antihypertensive medication Patients glycosylated haemoglobin ( HbA1c ) &gt; 12 % Patients normal sinus rhythm pacemaker , take antiarrhythmic drug complete bundle branch block , absolute QT QTc &gt; 500 msec Patients recent ( 60 day ) percutaneous transluminal coronary angioplasty ( PTCA ) , percutaneous coronary intervention ( PCI ) , coronary artery bypass grafting ( CABG ) , major surgical intervention Patients recent ( 60 day ) acute myocardial infarction , unstable angina , stroke transient ischaemic attack Patients CHF New York Heart Association grade III IV Patients lifethreatening arrhythmia include high risk QT/QTc prolongation family history Long QT Syndrome , severe hypokalaemia , etc . Patients positive hepatitis B surface antigen hepatitis C antibody Visit 1 ( screen ) abnormal liver function ( specifically ALAT/ASAT &gt; 1 x ULN ) Patients treated endothelin receptor antagonist 3 month prior screen Patients treat spironolactone eplerenone entry study Pregnant lactate woman Patients neoplasm deem live &lt; 12 month Patients history alcohol and/or drug abuse Patients know history major psychiatric condition would interfere conduct trial Patients active endocarditis and/or pericarditis Patients allergic avosentan endothelin receptor antagonist Patients participate another clinical study donate blood within 60 day randomise study .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>serum creatinine</keyword>
	<keyword>end stage renal disease</keyword>
	<keyword>cardiovascular mortality</keyword>
	<keyword>cardiovascular morbidity</keyword>
	<keyword>non-cardiovascular mortality</keyword>
	<keyword>non-cardiovascular morbidity</keyword>
</DOC>